Statements (58)
Predicate | Object |
---|---|
gptkbp:instanceOf |
intrauterine device
|
gptkbp:activeDuring |
levonorgestrel
|
gptkbp:approves |
contraception
|
gptkbp:assemblyLocation |
performed in a healthcare setting
|
gptkbp:availability |
prescription only
|
gptkbp:brand |
gptkb:Liletta
|
gptkbp:classification |
yes
|
gptkbp:clinicalTrials |
ACOG recommendations
used for long-term contraception Liletta_clinical_trial_results |
gptkbp:contraindication |
nausea
pregnancy headaches breast tenderness mood changes active pelvic infection uterine abnormalities |
gptkbp:decommissioningDate |
after 3 years or as needed
can be removed by a healthcare provider |
gptkbp:duration |
up to 3 years
|
gptkbp:effectiveDate |
over 99% effective
|
gptkbp:hasCapacity |
available through manufacturer
|
gptkbp:hasPopulation |
women of reproductive age
|
gptkbp:healthcare |
informed consent required
high satisfaction rates reported most users are in their 20s and 30s must be inserted by trained provider |
https://www.w3.org/2000/01/rdf-schema#label |
Liletta
|
gptkbp:impact |
may lighten periods
may stop periods altogether |
gptkbp:manufacturer |
Allergan
|
gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
gptkbp:notable_event |
required before insertion
|
gptkbp:offers |
varies by insurance
|
gptkbp:patentType |
yes
|
gptkbp:regulatoryCompliance |
approved_by_FDA
|
gptkbp:relatedPatent |
gptkb:Mirena
gptkb:Kyleena Skyla |
gptkbp:releaseDate |
2015
|
gptkbp:researchInterest |
ongoing studies on long-term effects
|
gptkbp:route |
intrauterine
|
gptkbp:runnerUp |
annual gynecological exams
recommended after insertion |
gptkbp:safetyFeatures |
generally considered safe
|
gptkbp:services |
pre-insertion counseling recommended
|
gptkbp:setIn |
during menstrual period
|
gptkbp:sideEffect |
expulsion
perforation cramping irregular bleeding |
gptkbp:triggerType |
prevents ovulation
thickens cervical mucus inhibits sperm motility |
gptkbp:userReviews |
generally positive
|